AMENDMENTS TO THE CLAIMS

Docket No.: 20241/0203932-US0

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Claim 1 (Currently Amended): A compound represented by the formula (1):

B-D-Z (1)

[wherein B represents the following formula (B-1), (B-2) or (B-3):(B-1):

A represents an imidazolyl or pyrazolyl group represented by the following formula (A-1), (A-2), (A-3) or (A-4), or may represent a hydrogen atom or R_1 when B is (B-3):(A-4):

$$(R_4)_S$$
 $N = N = (A-1)$
 $(R_5)_S$
 $(A-2)$

$$(R_4)$$
 t (R_5) t (R_6) $(A-4)$

(wherein R_4 and R_5 each independently represents a C_{1-6} alkyl group which may be substituted with G1, a C_{1-6} alkoxy group which may be substituted with G1, a C_{1-6} alkylsulfonyl group which may be substituted with G1, or a halogen atom; R_6 represents a hydrogen atom, a C_{1-6} alkyl group which may be substituted with G1, a C_{1-6} alkylcarbonyl group which may be substituted with G1, or a benzoyl group which may be substituted with G1, or a tetrahydropyranyl group;

G1 represents a cyano group, a formyl group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a monomethylamino group, a dimethylamino group or a halogen atom,

s represents 0 or an integer of 1 to 3,

t represents 0 or an integer of 1 or 2, and

 $R_4(s)$ or $R_5(s)$ may be the same or different when s or t is 2 or more);

 R_1 represents a halogen atom, a nitro group, a cyano group, a hydroxyl group, a C_{1-6} alkyl group which may be substituted with G2, a C_{1-6} alkoxy group which may be substituted with G2, a C_{1-6} alkylthio group which may be substituted with G2, a C_{1-6} alkylcarbonyl group which may be substituted with G2, an amino group (which may be substituted with one or two C_{1-6} alkyl groups), a benzoyl group which may be substituted with G2, or a benzyl group which may be substituted with G2;

 R_2 represents a C_{1-6} alkyl group which may be substituted with G2;

R₃ represents a hydrogen atom, a C₁₋₆-alkyl group which may be substituted with G2, a C₁₋₆ alkylcarbonyl group which may be substituted with G2, a benzoyl group which may be substituted with G2, or a benzyl group which may be substituted with G2;

G2 represents a cyano group, a formyl group, a hydroxyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxy group, a nitro group, an amino group, a monomethylamino group, a dimethylamino group or a halogen atom;

m represents 0 or an integer of 1 to 4, and $R_1(s)$ may be the same or different when m is 2 or more;

n represents 0 or an integer of 1 to 10,8, and $R_2(s)$ may be the same or different when n is 2 or more;

Docket No.: 20241/0203932-US0

o represents an integer of 1 or 2;1;

p represents 0 or an integer of 1 to 4, and R₁(s) may be the same or different when p is 2 or more;

q and r each independently represents an integer of 1 or 2;

in the formula (B-1), the dotted line represents a single bond or a double bond and does not simultaneously represent a double bond;

Y represents a carbon atom or a nitrogen atom, which may have a substituent or a multiple bond that satisfies a valence;

E represents an oxygen atom, a sulfur atom or the following formula (1a) when Y represents a carbon atom;

$$\begin{array}{c|c}
O & R_{60} \\
\hline
C & j & R_{60} \\
\hline
R_{1} & C & R_{7} \\
\hline
R_{2} & C & R_{1}
\end{array}$$
(1a)

(wherein R_{60} represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group (which may be substituted with a nitro group, a halogen atom, a hydroxyl group, a C_{1-6} alkoxy group, or a C_{1-6} alkyl group); R_7 and R_8 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynyloxy group, a C_{1-6} acyloxy group, a C_{3-6} cycloalkyl group which may be substituted with G_2 , or a phenyl group which may be substituted with G_2 ;

j and k independently represent 0 or an integer of 1, and j and k represent 0 when B is (B-2);1;

1 represents 0 or an integer of 1 to 16;

 $R_7(s)$ and $R_8(s)$ may be the same or different when 1 is 2 or more);

E represents the formula (1a) when Y represents a nitrogen atom;

Docket No.: 20241/0203932-US0

D represents an oxygen atom, a sulfur atom or the formula (1a);

X represents an oxygen atom, the formula: SOu (wherein u represents 0 or an integer of 1 or 2) or the formula: N-R₉ (wherein R₉ represents a hydrogen atom, a C₁₋₆ alkyl group which may be substituted with G2, or a benzyl group which may be substituted with G2);

Z represents a chroman 2-yl group which is substituted with G3, a chroman 4-yl group which is substituted with G3, a 2,3-dihydrobenzofuran-2-yl group which is substituted with G3, or a 2,3-dihydrobenzofuran-3-yl group which is substituted with G3, a thiochroman 2-yl group which is substituted with G3, a 2,3-dihydrobenzothiophene-2-yl group which is substituted with G3, a thiochroman 4-yl group which is substituted with G3, a 2,3-dihydrobenzothiophene-3-yl group which is substituted with G3, or a 1,3-benzoxathiol-2-yl group which is substituted with G3;

G3 represents the formula: NHR₁₀ {wherein R₁₀ represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group (which may be substituted with a nitro group, a halogen atom, a hydroxyl group, a C_{1-6} alkoxy group, or a C_{1-6} alkyl group)};

or the formula: OR11

{wherein R_{11} represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group (which may be substituted with a hydroxyl group, a C_{1-6} alkoxy group, a halogen atom, or a C_{1-6} alkyl group)}]

or a pharmaceutically acceptable salt thereof.

Claim 2 (Currently Amended): The compound according to claim 1, wherein Z represents a group represented by the following formula (Z-1), (Z-2), (Z-3), (Z-4)(Z-2) or (Z-5):

Application No. 10/566,820 Amendment dated July 14, 2008 Reply to Non-Final Office Action of April 15, 2008

(Z-5)

Docket No.: 20241/0203932-US0

[wherein * represents an asymmetric carbon atom; X_1 represents an oxygen atom or a sulfur atom; R_{12} to $R_{32}R_{16}$ to R_{19} and R_{28} to R_{32} each independently represents a hydrogen atom or a C_{1-6} alkyl group, and

G3 is as defined above]represents the formula: NHR₁₀

{wherein R_{10} represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group (which may be substituted with a nitro group, a halogen atom, a hydroxyl group, a C_{1-6} alkoxy group, or a C_{1-6} alkyl group)};

or the formula: OR11

{wherein R_{11} represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group (which may be substituted with a hydroxyl group, a C_{1-6} alkoxy group, a halogen atom, or a C_{1-6} alkyl group)}]

or a pharmaceutically acceptable salt thereof.

Claim 3 (**Original**): An antioxidant comprising, as the active ingredient, one or more compounds or pharmaceutically acceptable salts thereof according to claim 1 or 2.

Docket No.: 20241/0203932-US0

Claim 4 (Currently Amended): A therapeutic agent method for kidney diseases, wherein the method comprises using a therapeutic agent comprising the antioxidant according to claim 3.

Claims 5 (Currently Amended): A therapeutic agentmethod for cerebrovascular diseases, wherein the method comprises using a therapeutic agent comprising the antioxidant according to claim 3.

Claim 6 (Current Amended): A therapeutic agent method for circulatory diseases, wherein the method comprises using a therapeutic agent comprising the antioxidant according to claim 3.

Claim 7 (Currently Amended): A therapeutic agent method for cerebral infarction, wherein the method comprises using a therapeutic agent comprising the antioxidant according to claim 3.

Claim 8 (Currently Amended): A therapeutic agentmethod for retinal oxidative damage, wherein the method comprises using a therapeutic agent comprising the antioxidant according to claim 3.

Claim 9 (Currently Amended): A therapeutic agentmethod according to claim 8, wherein the retinal oxidative damage is age-related macular degeneration or diabetic retinopathy.

Application No. 10/566,820 Amendment dated July 14, 2008 Reply to Non-Final Office Action of April 15, 2008

Claim 10 (Currently Amended): A method for inhibiting production of lipoxygenase, wherein the method comprises using a lipoxygenase inhibitor comprising the antioxidant according to claim 3.

Docket No.: 20241/0203932-US0

Claim 11 (Currently Amended): A method for inhibiting production of a 20-hydroxyeicosatetraenoic acid (20-HETE) synthase, wherein the method comprises using 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor comprising the antioxidant according to claim 3.